Key Highlights

  • WAY reported third-quarter 2026 Revenue of $325.6 million, up 21% from $268.7 million, with organic growth of 10%.
  • Net income was $31.0 million, or $0.16 per diluted share, and adjusted EBITDA rose 24% to $139 million.
  • Subscription revenue grew 34% to $181 million, while volume-based revenue rose 8% to $143 million.
  • Full-year adjusted EBITDA guidance was raised to $543 million to $549 million, up $6 million at the midpoint.
  • Full-year revenue is guided to $1.277 billion to $1.287 billion, implying about 6% growth in the fourth quarter.

Revenue Climbs 21% to $325.6 Million While Organic Growth Holds at 10%

Waystar (NASDAQ:WAY) reported results for the third quarter ended Sep 30, 2026 on Nov 2, 2026, with revenue of $325.6 million versus $268.7 million a year earlier. Organic growth was 10%, which management said reflects about 1 point of pressure from three large client implementations that ramped unusually quickly in the prior-year period.

Waystar provides cloud-based software that helps healthcare providers manage claims, patient access and payments across the revenue cycle. Its network processes more than 8.5 billion transactions a year, representing over $3 trillion in gross claims.

Income from operations was $61.3 million, and Net Income was $31.0 million compared with $30.6 million a year ago. Non-GAAP net income was $87.1 million, or $0.44 per diluted share.

Subscription Revenue Up 34% as Patient Payments Slow With the Shift to Digital Statements

Subscription revenue was $181 million, up 34%, or 12% organically. Volume-based revenue rose 8% to $143 million, improving from the second quarter and in line with expectations.

Provider revenue grew 28% to $243 million, or 11% organically, while patient payments revenue rose just 5% to $82 million as providers move from printed to digital statements. Net revenue retention was 108%, within its historical range.

Clients generating more than $100,000 of trailing 12-month revenue reached 1,488, up 14%. Year-to-date bookings grew 25%, and the company said it signed the largest new client win in its history, a health system with about $7 billion in annual net patient revenue.

Adjusted EBITDA Margin of 43% and $115 Million of Unlevered Free Cash Flow

Adjusted EBITDA grew 24% to $139 million, a 43% margin, which management tied to operating leverage, cost discipline and favorable revenue mix. Cash Flow from operations was $104 million, unlevered free cash flow was $115 million, and Capital spending was $10 million.

Waystar ended the quarter with about $277 million of cash and short-term investments and net leverage of 2.2 times, more than one full turn lower than a year ago. It repurchased about $21 million of stock in the quarter, bringing total Buybacks under a $200 million authorization to roughly $33 million.

For the nine months, revenue was $959.2 million, up from $795.7 million, and net income was $115.2 million versus $92.1 million.

Three Factors Trim Fourth-Quarter Growth by About 4 Points

The company now expects full-year revenue of $1.277 billion to $1.287 billion, which implies fourth-quarter revenue near $323 million and growth of about 6%. Management cited the print-to-digital shift in patient payments, a slower revenue ramp from Iodine as activity moves toward Prebill Anomaly Detection, and the tough prior-year comparison, which together cost about 4 points. Without them, fourth-quarter growth would be near 10%.

Adjusted EBITDA is guided to $543 million to $549 million, implying a fourth-quarter margin near 42%, and capital expenditures are expected at $55 million to $60 million. Management said larger platform deals can take 12 to 18 months to convert to revenue and plans to give added context with its formal outlook next quarter.